Background The mainstays of cutaneous leishmaniasis (CL) treatment, in several world
regions, are pentavalent antimony (Sbv) compounds administered parenterally, despite their …

It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …

The first choice drugs for the treatment of cutaneous and mucocutaneous leishmaniasis are
pentavalent antimonials, sodium stibogluconate, or meglumine antimoniate. However, the …

This review presents an survey to the biological importance of sesquiterpene lactones (SLs)
in the fight against four infectious neglected tropical diseases (NTDs)—leishmaniasis …

A novel therapy, intralesional (IL) pentamidine, was compared to intralesional therapy with
antimony (ILSb), a World Health Organization–recommended therapy, for single Bolivian …

Background Treatment of cutaneous leishmaniasis (CL) remains challenging since the
drugs currently used are quite toxic, thus contributing to lethality unrelated to the disease …

Although intralesional meglumine antimoniate (MA) infiltration is considered an option for
cutaneous leishmaniasis (CL) therapy and is widely used in the Old World, there have been …

Sodium stibogluconate (SSG, Pentostam) and meglumine antimoniate (MA, Glucantime) are
two antimonials that are widely used to treat cutaneous leishmaniasis (CL), but the relative …

Cutaneous leishmaniasis (CL) is not a life-threatening condition. However, its treatment can
cause serious adverse effects and may sometimes lead to death. Recently, safer local …

BACKGROUND Cutaneous leishmaniasis (CL) is a world-wide health problem which
currently lacks effective, affordable and easy to use therapy. Recently, the meglumine …